<DOC>
	<DOCNO>NCT01000740</DOCNO>
	<brief_summary>The primary objective describe quality life long-term survivor terminate EAP .</brief_summary>
	<brief_title>A Study Long Term Survivals Expand Access Program ( EAP ) Iressa</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Provision inform consent prior study specific procedure . Participated Iressa EAP China . Diagnosed NSCLC . Patients start EAP least 3 year study initiate yet terminate EAP ( active longterm survivor ) . Patients consent provide blood sample available archival tumour tissue sample EGFR gene test ( provision tumour tissue sample optional ) . Patients disagree participate study . Patients whose medical objection record use exist data medical practice scientific research .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>EAP</keyword>
	<keyword>Long term survival ( 3 year )</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>efficacy</keyword>
</DOC>